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Recent studies suggest that Cu/Zn superoxide dismutase (SOD1)
could be pathogenic in both familial and sporadic amyotrophic
lateral sclerosis (ALS) through either inheritable or nonheritable
modiﬁcations. The presence of a misfolded WT SOD1 in patients
with sporadic ALS, along with the recently reported evidence that
reducing SOD1 levels in astrocytes derived from sporadic patients
inhibits astrocyte-mediated toxicity on motor neurons, suggest
that WT SOD1 may acquire toxic properties similar to familial ALS-
linked mutant SOD1, perhaps through posttranslational modiﬁca-
tions. Using patients’ lymphoblasts, we show here that indeed WT
SOD1 is modiﬁed posttranslationally in sporadic ALS and is iper-
oxidized (i.e., above baseline oxidation levels) in a subset of
patients with bulbar onset. Derivatization analysis of oxidized car-
bonyl compounds performed on immunoprecipitated SOD1 iden-
tiﬁed an iper-oxidized SOD1 that recapitulates mutant SOD1-like
properties and damages mitochondria by forming a toxic complex
with mitochondrial Bcl-2. This study conclusively demonstrates the
existence of an iper-oxidized SOD1 with toxic properties in patient-
derived cells and identiﬁes a common SOD1-dependent toxicity be-
tween mutant SOD1-linked familial ALS and a subset of sporadic
ALS, providing an opportunity to develop biomarkers to subclassify
ALS and devise SOD1-based therapies that go beyond the small
group of patients with mutant SOD1.
Amyotrophic lateral sclerosis (ALS) is characterized by de-generation and loss of upper and lower motor neurons,
leading to paralysis and death by 3–5 y after diagnosis (1). The
majority of ALS cases are sporadic (sALS), with no apparent
hereditary contribution; only 5%of cases are familial (fALS), with
genetic mutations dominantly inherited (2, 3). Disease-causing
mutations in various genes have been identiﬁed (4–6); abundant
among these are mutations in the gene encoding for Cu/Zn su-
peroxide dismutase (SOD1) (7). It is now established thatmutated
SOD1 (mutSOD1) acquires new toxic functions, most likely
through mutation-driven conformational changes (8, 9). Despite
multiple epidemiologic studies investigating possible correlations
between environmental and/or genetic triggers and sALS, the
etiology of sALS remains unknown (10). Thus, it is imperative that
we at least ﬁnd markers of disease for patients with sALS.
The two forms, fALS and sALS, are clinically indistinguishable
and share many pathological abnormalities (11), suggesting com-
mon disease mechanisms and possibly common triggers. SOD1
has been proposed as such a common trigger (12). It has been
suggested that either age- or environmental-dependent post-
translational modiﬁcations lead to conformational rearrange-
ments in the structure of WT SOD1 that are similar to those
imparted by disease-causative SOD1mutations in fALS, resulting
in a similar gain of toxic pathogenic functions (13). For instance,
in cultured cells, oxidized WT SOD1 forms proteinaceous aggre-
gates that trigger cell death (14). Moreover, Zn-depleted WT
SOD1 induces death of cultured motor neuron and metal-de-
ﬁcient WT SOD1 conforms, similar to mutSOD1, in an unstable
and aggregation-prone structure (15). The use of conformation-
speciﬁc antibodies raised against fALS-linkedmutSOD1has led to
the detection of atypicalWTSOD1 species in a subset of sALS (16,
17). In vitro, these mutSOD1-speciﬁc conformational antibodies
also recognize the oxidized form of recombinant WT SOD1,
suggesting that the WT SOD1 detected in sALS patients may be
oxidized as well (17). Bosco et al. (17) recently reported that,
similar to fALS-linked mutSOD1, recombinant oxidized WT
SOD1 inhibits kinesin-based axonal transport in isolated squid
axoplasm, suggesting a common mechanism of toxicity in mutant
and oxidatively modiﬁed WT SOD1 in vitro. Although the fore-
going studies suggest that oxidized SOD1, formed perhaps as
a consequence of environmental- or age-related factors, could
trigger or affect the course of sALS, evidence of the presence of
oxidized SOD1 in sALSpatients remains circumstantial. Similarly,
whetherWT SOD1 inclusion is a pathological occurrence or gains
pathogenic relevance perhaps by targeting the same intracellular
pathways as the disease-causative mutSOD1 is unclear.
Here we decisively report the presence of an over-oxidized WT
SOD1 in a subset of sALS patients. Using Epstein–Barr virus
(EVB)-immortalized lymphocytes (lymphoblasts) (18), we found
that WT SOD1 is signiﬁcantly more oxidized above baseline oxi-
dation in a group of sALS patients with bulbar onset compared
with non-neurologic controls, mutSOD1-derived patients, and
patients with non-bulbar sALS. We term this over-oxidized SOD1
iper-oxidized SOD1 (iperOxSOD1). We found that induction of
oxidative stress by treating lymphoblasts with hydrogen peroxide
(H2O2) did not further increase the iperOxSOD1 oxidative state,
although it did trigger iperOxSOD1 aggregation and formation of
a toxic complex with mitochondrial Bcl-2, similar to the complex
that we recently reported for fALS-linked mutSOD1 (19). Like
mutSOD1 (20) and other toxic proteins (21, 22), iperOxSOD1
induces a conformational change in Bcl-2 that exposes the toxic
BH3 domain, damaging the lymphoblast mitochondria.
Our data demonstrate the presence of an iper-oxidized form of
SOD1 in a subset of sALS patients with bulbar onset and con-
clusively conﬁrm, in patient-derived cells, the potential of WT
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SOD1 to become pathogenic through a disease-speciﬁc post-
translational modiﬁcation. IperOxSOD1 and the toxic complex
with Bcl-2 were not detected in all sALS samples, suggesting that
modiﬁed SOD1 (and toxicity of the iperOxSOD1/Bcl-2 complex)
may be involved in a subset of sALS cases by analogy with mut-
SOD1, which accounts for only ∼25% of fALS cases. Thus, our
data highlight the existence of a converging pathogenic pathway
between a portion of fALS and sALS cases, leading to the pos-
sibility of subclassifying ALS based on the identiﬁcation of spe-
ciﬁc biomarkers. Moreover, taken together with recent data
showing that SOD1 can be targeted therapeutically in sporadic
ALS (23), our ﬁnding that Bcl-2 becomes a toxic target of iper-
OxSOD1 through the same mechanism as mutSOD1 (20) can
permit the design of target-based therapies against the SOD1/Bcl-
2 complex with efﬁcacy possibly exceeding that of therapies for
the small percentage of patients with mutSOD1.
Results
WT SOD1 Is iper-Oxidized in a Subset of sALS Patients. Correlative
evidence suggests the potential for oxidization of WT SOD1 in
sALS (17). The correlation is based on the observation that
antibodies positive for a misfolded WT SOD1 in sALS spinal
cord sections also recognize recombinant oxidized SOD1 (17)
in vitro. However, thus far no hard evidence of the existence of
such oxidized SOD1 in sALS patients has been published. To
determine whether WT SOD1 is indeed oxidized in sALS, we
performed derivatization analyses of carbonyl compounds with
2,4-dinitrophenylhydrazine (DNPH) on SOD1 immunoprecipi-
tated from lymphoblasts derived from sALS patients, mutSOD1-
fALS patients, and healthy control subjects. DNPHWestern blot
analysis is a sensitive method for detecting oxidized carbonyl
groups in the protein of interest (22–24). We found that at
baseline (without oxidative stress), SOD1 oxidization was greater
in a subset of sALS patients with bulbar onset compared with
mutSOD1-fALS patients and controls (Fig. 1A). On densito-
metric analysis, this group of sALS patients (termed iper-
OxSOD1-sALS) exhibited a twofold increase in baseline SOD1
oxidation (P < 0.05) compared with mutSOD1-fALS patients,
non-neurologic controls (Fig. 1B), and other sALS patients. This
increased WT SOD1 oxidation is a speciﬁc effect and not a gen-
eralized phenomenon affecting several proteins; the total car-
bonyl content showed no differences in global protein oxidative
levels (Fig. 1C). To determine whether iperOxSOD1 could re-
spond to further oxidation, we treated lymphoblasts from these
patients with H2O2. In contrast to normally oxidized or mutSOD1
lymphoblasts, the iperOxSOD1 lymphoblasts did not respond to
treatment (Fig. 1 A and B), suggesting that maximum oxidation
had already occurred. Seven of the 20 sALS cases analyzed in the
present study displayed iperOxSOD1 (Table 1). Initial analysis
showed a correlation between iperOxSOD1 and site of disease
onset, with all seven iperOxSOD1-sALS patients diagnosed
with bulbar ALS. We found no correlations between the ap-
pearance of iperOxSOD1 and patient sex, age of onset, or dura-
tion of disease progression.
IperOxSOD1 Aggregates in Lymphoblasts of a Subset of sALS
Patients. It was previously reported that in vitro, a posttransla-
tionally modiﬁed WT SOD1 becomes unstable and undergoes
misfolding and aggregation in a mutSOD1-like fashion (13). Ac-
cordingly, we performed immunoﬂuorescence analysis of iper-
OxSOD1-sALS lymphoblasts and compared the patterns of aggre-
gation in iperOxSOD1 and mutSOD1. We found SOD1-positive
inclusions in lymphoblasts of iperOxSOD1-sALS and mutSOD1-
fALS patients (Fig. 2A, a–c), but no SOD1 inclusions in lympho-
blasts of control subjects (Fig. 2A, g) or the other sALS patients
(Fig. 2A, e). Treatment with H2O2 did not change the aggregation
pattern of iperOxSOD1 (Fig. 2A, d) or of mutSOD1 (Fig. 2A, b);
however, it did induce SOD1 aggregation in lymphoblasts of con-
trol subjects and the other sALS patients (Fig. 2A, f–h), although
these aggregates were more diffuse and not as well deﬁned as
those seen at baseline in iperOxSOD1-sALS and mutSOD1-fALS
patients. Thus, given that oxidative stress induced aggregation
of WT SOD1, our ﬁndings suggest that the aggregation of SOD1
that we observed in the seven sALS patients with bulbar onset at
baseline is a consequence of disease-induced stress.
IperOxSOD1 Acquires mutSOD1-Like Toxic Properties and Aggregates
with Mitochondrial Bcl-2. Numerous toxic properties have been
attributed to mutSOD1. If mutSOD1 and iperOxSOD1 share
toxic properties, then this toxicity must converge to common
intracellular molecular targets, possibly damaging the same
organelles in cells. We examined mitochondria as a converging
point of toxicity for two reasons: (i) Mitochondrial defects are
a common feature of sALS and fALS, with mitochondrial de-
generation, vacuolization, and swelling documented in both
sALS and fALS patients as well as in mutSOD1 mice models of
ALS (25), and (ii) we recently reported an aberrant toxic in-
teraction between mutSOD1 and mitochondrial Bcl-2 and found
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Fig. 1. Identiﬁcation of an iper-oxidized SOD1 in a subset of sALS patients.
(A) Representative immunoblot of SOD1 oxidation detected by a de-
rivatization assay of carbonyl compounds. Proteins extracted from sALS,
fALS, and healthy control lymphoblasts, before and after H2O2 treatment,
were precipitated with rabbit anti-SOD1 antibody and analyzed by Western
blot using anti-DNPH (Upper) and sheep anti-SOD1 (Lower) antibodies. (B)
Ratio of DNPH and precipitated SOD1. For each patient’s line, samples were
analyzed in triplicate in three independent blots (with and without H2O2),
and densitometric analysis was performed on each blot. The graph represents
the mean ± SD SOD1 oxidation for each experimental group. ANOVA revealed
signiﬁcantly higher oxidized SOD1 in a group of sALS lymphoblasts compared
with lymphoblasts from mutSOD1-fALS and healthy controls (*P < 0.05). (C)
Representative blot of derivatization assay of carbonyl compounds on total
protein content from fALS, sALS, and healthy control lymphoblasts before and
after H2O2 treatment, showing no differences in total oxidation levels.
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that mutSOD1 relies on this interaction to damage the mito-
chondria (20). We also showed that formation of the toxic
mutSOD1/Bcl-2 complex is mitochondria-speciﬁc and driven by
conformational changes of the unstable mutSOD1 (20). Conse-
quently, we conducted co-immunoprecipitation experiments to
determine whether iperOxSOD1 aberrantly binds with Bcl-2 in
mitochondria from iperOxSOD1-sALS patients. We ﬁrst con-
ﬁrmed the interaction between SOD1 (WT and mutant) and Bcl-
2 in lymphoblasts of ALS patients and controls. We found that
monomeric SOD1 co-immunoprecipitated with Bcl-2 from mi-
tochondria isolated from mutSOD1-fALS, sALS (with or with-
out iperOxSOD1), and control lymphoblasts (Fig. 2B). Based on
our previous report that misfolded mutSOD1 aberrantly binds
Bcl-2 forming a high molecular weight SDS-resistant complex
with Bcl-2 (19), we expected misfolded iperOxSOD1 (but not
regular SOD1) to similarly form insoluble high molecular weight
complexes with Bcl-2. Although we conﬁrmed the presence of
a high molecular weight SDS-resistant SOD1/Bcl-2 complex in
lymphoblasts of mutSOD1 patients, we did not detect these
aggregates in iperOxSOD1-positive lymphoblasts (Fig. 2B), sug-
gesting that iperOxSOD1 can act only partly like mutSOD1,
perhaps by initially becoming unstable and only later maturing
into a mutSOD1-like toxic molecule through exposure to addi-
tional stressors. To test this hypothesis, we treated lymphoblasts
with H2O2 and found that on exposure to further oxidative
stress, iperOxSOD1 formed high molecular weight SDS-resistant
aggregates with Bcl-2 (Fig. 2B, arrow), whereas no aberrant
aggregates of SOD1 and Bcl-2 were detected in control cells
(Fig. 2B). This ﬁnding indicates that although oxidative stress
does not change the oxidative state of the already iper-oxidized
SOD1 (Fig. 1), it does trigger features similar to those seen in
ALS-causative SOD1 mutations. Confocal microscopy analysis
of H2O2-treated lymphoblasts showed colocalization of SOD1
and Bcl-2 within cellular aggregates (Fig. 3, g and h). We found
inclusions immunopositive for both SOD1 and Bcl-2 in mut-
SOD1 and iperOxSOD1-sALS lymphoblasts (Fig. 3, a, b, d, and
e), but not in lymphoblasts from sALS patients without iper-
OxSOD1 (Fig. 3, c–f). Moreover, visual inspection showed lower
overall expression of SOD1 and less evident colocalization of
SOD1 and Bcl-2 in these non-iperoxSOD1 sALS groups (Fig. 3, i).
OxSOD1 Requires Bcl-2 to Damage in Vitro Isolated Mitochondria.
MutSOD1 relies on mitochondrial Bcl-2 to damage in vitro
isolated mitochondria (20). To determine whether over-oxidized
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Fig. 2. Like mutSOD1, iperOxSOD1
aggregates in patient cells. (A) SOD1 ap-
pearance in lymphoblasts of sALS,
mutSOD1-fALS, and controls analyzed
by immunoﬂuorescence using a rabbit
antiSOD1antibody. Confocal experiments
revealed SOD1-positive aggregates
(arrows) in both mutSOD1-fALS and
iperOxSOD1-sALS patients before (a and
c) and after (b and d) H2O2 treatment
(100 μM, 2 h). Control and sALS lym-
phoblasts exhibited SOD1 aggregation
only after H2O2 treatment (f–h). (B) Per-
centage (± SD) of cells containing SOD1-
positive aggregates before and after
H2O2 treatment. Counting was done
selecting seven different ﬁelds for each
group. MutSOD1-fALS and iperOxSOD1-
sALS patients showed a signiﬁcantly
higher percentage of cells containing
aggregates compared with both remain-
ing sALS and control patients (P <
0.0001). (C) Representative blots show-
ing the aberrant bond of SOD1 and Bcl-2
in mutSOD1-fALS and iperOxSOD1-sALS
patients (arrows). Proteins extracted
from fALS, iperOxSOD1-sALS, and con-
trol lymphoblasts treated with 100 μM
H2O2 were precipitated as above, and
membranes were stained with mouse
anti–Bcl-2 antibody (Upper). SOD1 pre-
cipitation was conﬁrmed by restaining
the blot with a sheep anti-SOD1 antibody (Lower). After H2O2 treatment, high molecular weight aggregates positive for both Bcl-2 (Upper) and SOD1 (Lower)
were detected in mutSOD1-fALS and iperOxSOD1-sALS patients, but not in healthy controls (or the remaining sALS patients). The SOD1/Bcl-2 complex was
recovered in the presence of the precipitating antibody, but not with the corresponding IgGs, indicating speciﬁcity of the binding. TL, total lysate.
Table 1. iperOxSOD1-sALS appears to correlate with bulbar onset
Total Men Women
No. of ALS patients 24 (4 fALS) 12 (2 fALS) 8 (2 fALS)
Age of onset (mean ± SE) 55.0 ± 2.5 55.9 ± 2.2 53 ± 2.8
Illness duration (mo ± SE) 40.5 ± 4.9 42.7 ± 4.7 38.3 ± 5.0
Site of onset 9 LL; 4 UL; 7 B 6 LL; 3 UL; 3 B 2 LL; 2 UL; 4 B
Patients with iperOxSOD1 0 LL; 1 UL; 7 B 0 LL; 0 UL; 3 B 0 LL; 1 UL; 4 B
Response to H2O2 9 LL; 3 UL; 0 B 6 LL; 3 UL; 0 B 2 LL; 2 UL; 0 B
B, bulbar; LL, lower limb; UL, upper limb.
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SOD1 has similar damaging properties to mitochondria through
the aberrant complex with Bcl-2, we incubated recombinant
oxSOD1 with mitochondria isolated from HEK293T cells, which
do not express endogenous detectable levels of Bcl-2 (20, 21),
and mitochondria from HEK293T cells transfected with Bcl-2.
Mitochondrial damage was examined by ELISA, with the amount
of cytochrome C released from mitochondria measured. Similar
to what we reported previously for mutSOD1 (20), oxSOD1 in-
duced cytochrome C release only from Bcl-2–positive mito-
chondria (Fig. 4A). In contrast to oxSOD1, WT SOD1 did not
cause the release of cytochrome C (26) from either Bcl-2–nega-
tive or Bcl-2–positive mitochondria (Fig. 4A). Thus, iperOxSOD1
and mutSOD1 share a common mechanism of mitochondrial
toxicity that requires the formation of a toxic complex with mi-
tochondrial Bcl-2.
Given our ﬁnding that mutSOD1 induces a toxic conforma-
tional change in Bcl-2 exposing the otherwise hidden BH3 toxic
domain, we wished to determine whether iperOxSOD1 behaves
similarly, transforming Bcl-2 into a toxic protein. We immuno-
precipitated H2O2-treated lymphoblasts using two anti-Bcl-2
(αBcl-2) conformation-speciﬁc antibodies: (i) the αBcl-2/pocket
antibody, which recognizes Bcl-2 in its normal, prosurvival con-
formation, and (ii) the αBcl-2/BH3 antibody, which does not
recognize Bcl-2 unless it undergoes a toxic conformational change
to expose the BH3 domain (20). The amount of Bcl-2 immuno-
precipitated by αBcl-2/pocket antibody was signiﬁcantly lower in
lymphoblasts from iperOxSOD1-sALS patients compared with
controls, which included lymphoblasts from both healthy indi-
viduals and sALS patients without iperOxSOD1 (Fig. 4B). Ac-
cordingly, αBcl-2/BH3 precipitates Bcl-2 to a greater extent in
iperOxSOD1-sALS lymphoblasts than in control lymphoblasts
(Fig. 4B). We also used mutSOD1-fALS lymphoblasts as a posi-
tive control (Fig. 4B, Left) to set the BH3/pocket ratio. Densito-
metric analysis found a higher BH3/pocket ratio in iperOxSOD1-
sALS lymphoblasts than in lymphoblasts from controls and sALS
patients without iperOxSOD1, with the highest ratio seen in
mutSOD1-fALS cells (Fig. 4C). We conﬁrmed this ﬁnding by
ﬂow cytometry using αBcl-2/BH3 antibody to sort cells based on
exposure of the BH3 domain (Fig. 4D). Expression of the toxic
BH3 domain was higher in iperOxSOD1-sALS lymphoblasts
than in controls (Fig. 4D). As revealed by immunoprecipitation
analyses (Fig. 4 B and C), the BH3/pocket ratio in iperOxSOD1-
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Fig. 3. Like mutSOD1, iperOxSOD1 colocalizes and aggregates with Bcl-2 in
patient cells. Colocalization of SOD1 and Bcl-2 was evaluated by immuno-
ﬂuorescence with rabbit anti-SOD1 (A–C) and mouse anti-Bcl-2 (D–F) anti-
bodies. The merging signals show colocalization of the two proteins within
the aggregates in iperOxSOD1-sALS and mutSOD1-fALS patients after H2O2
treatment (G and H, arrows). sALS lymphoblasts with no iperOxSOD1 and no
SOD1/Bcl-2 high molecular weight aggregates did not demonstrate coloc-
alization of the two proteins (C, F, and I).
mutSOD1 
fALS
IperOx
SOD1sALS 
sALS control 
** 
* 
A 
Pocket  Pocket Pocket Pocket Pocket BH3 BH3 BH3 BH3 BH3
WB: 
Bcl-2 
WB: 
Bcl-2 
IP: 
mutSOD1 
fALS 
sALS IperOxSOD1 
sALS control control 
IperOxSOD1- 
sALS
mutSOD1- 
fALScontrol 
- Bcl-2 + Bcl-2 
B D 
C 
400 
300 
200 
100 
0.0 
Fig. 4. oxSOD1-mediated toxicity requires binding
with Bcl-2 and induces a toxic rearrangement of Bcl-
2 structure. (A) In isolated mitochondria, recombi-
nant oxSOD1 induces cytochrome C release only in
the presence of Bcl-2. Bcl-2–negative or Bcl-2–posi-
tive mitochondria isolated from HEK293T cells
were incubated with 5 μL of recombinant oxSOD1
for 30 min. Cytochrome C immunoreactivity was
measured in supernatants by ELISA. OxSOD1, but
not WT SOD1, caused an increase in cytochrome C
release from damaged mitochondria. Data are
mean ± SD of three independent experiments per-
formed in duplicate (P < 0.05) with CaCl2 as a posi-
tive control for maximal cytochrome C release. (B)
Representative blot showing that Bcl-2 is con-
formationally modiﬁed in lymphoblasts of iper-
OxSOD1-sALS and mutSOD1-fALS patients. In
mutSOD1-fALS and iperOxSOD1-sALS lymphoblasts,
there is increased exposure of the toxic BH3 domain
paralleled by decreased exposure of the pocket re-
gion, indicating a conformational change in the
Bcl-2 protein. (C ) Densitometric analysis of the BH3/
pocket ratio. Each patient’s line was analyzed in
three independent experiments. The graph repre-
sents BH3 and pocket exposure normalized on the
total amount of Bcl-2 in all samples. The BH3/pocket
ratio was signiﬁcantly higher in mutSOD1-fALS and
iperOxSOD1s-ALS lymphoblasts compared with con-
trol and other sALS lymphoblasts. *P < 0.05; **P <
0.0001. (D) Exposure of BH3 domain also was as-
sessed by ﬂow cytometry using the conformation-
speciﬁc anti-BH3 antibody. The shift in ﬂuorescence of mutSOD1-fALS and iperOxSOD1-sALS lymphoblasts compared with controls indicates increased
exposure of the BH3 domain.
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sALS lymphoblasts was between that in mutSOD1-fALS (highest
ratio) and control (lowest ratio) lymphoblasts.
We next determined whether the iperOxSOD1/Bcl-2 complex
acquired toxic properties that could compromise the integrity of
mitochondria in iperOxSOD1-sALS patients. We examined mi-
tochondrial morphology by transmission electron microscopy in
H2O2-treated iperOxSOD1-sALS lymphoblasts and found that, in
contrast to control lymphoblasts, where H2O2 treatment triggered
WT SOD1 oxidation but not formation of the SOD1/Bcl-2 com-
plex, iperOxSOD1-sALS cells showed considerable mitochondrial
damage (Fig. 5, Upper). Control lymphoblasts exhibited normally
shaped mitochondria with elongated structure and organized
cristae (Fig. 5, Lower). In iperOxSOD1-sALS lymphoblasts, few
intact mitochondria were detected. In the few structures reminis-
cent of mitochondria, vacuoles and a completely disorganized
outer and inner membrane structure were seen (Fig. 5, Upper).
Discussion
The lack of reliable biomarkers precludes a complete un-
derstanding of the etiology of sALS. As for sALS, the etiology of
fALS is heterogeneous, with different subgroups of fALS caused
by mutations in different genes (27). Although studies in animal
and cellular models of mutSOD1-fALS have advanced our un-
derstanding of the disease, critical questions remain: How well
do these models represent the totality of ALS? Are the toxic
mechanisms identiﬁed in a fraction of fALS relevant to sALS?
Are all sALS cases equal or, like fALS, can sALS be subclassiﬁed
based on different primary causes? Do all forms of ALS share
the same pathogenic mechanisms despite being set off by differ-
ent triggers? A common assumption is that pathogenic mecha-
nisms must converge because the different forms of ALS are
clinically indistinguishable. Supporting this idea, glutamate exci-
totoxicity and mitochondria dysfunction are shared by fALS and
sALS (25, 28, 29). In addition, mutations and proteinaceous in-
clusions of TDP-43 and FUS, and more recently of ubiquilin 2,
have been identiﬁed in both fALS and sALS (30, 31). No genetic
mutations of SOD1 have been found in sALS patients, despite the
occurrence of SOD1 proteinaceous inclusions (32). In the ab-
sence of SOD1 mutations in sALS, we cannot determine whether
WT SOD1-positive inclusions are pathogenic or simply a patho-
logical ﬁnding. The fact that these inclusions resemble those
formed by fALS-linked mutSOD1 has been recently proposed
as an indication of their pathogenicity, and triggering by aging
or other ALS disease-associated posttranslational modiﬁcations,
most likely oxidation, has been suggested (17). However, whether
WT SOD1 is indeed oxidized in patients and eventually acquires
toxic properties that make it pathogenic remains unknown.
Here we conclusively show that WT SOD1 is posttranslation-
ally modiﬁed and iper-oxidized in a subset of sALS patients, and
that through this oxidation, modiﬁed SOD1 acquires toxic prop-
erties similar to those induced by disease-causing genetic muta-
tions in patient-derived cells. First, the iper-oxidation of SOD1 is
speciﬁc, not generalized to all ALS patients but occurring only in
a subset of patients with bulbar onset (iperOxSOD1-sALS). Thus,
oxidation is not a secondary phenomenon triggered by global
metabolic changes associated with the disease. Second, iper-oxi-
dation is not a phenomenon triggered by different culturing and
cloning conditions in immortalized lymphoblasts. Indeed, re-
alizing that these cells may have varying biochemical phenotypes
independent of disease but induced by different culturing con-
ditions, we standardized our EVB immortalization protocol,
experimental procedures, and culturing conditions among the
different patient lines. Third, in iperOxSOD1-sALS patients,
oxidation is not an overall age-associated phenomenon that tar-
gets other proteins; rather, it is directed toward the one protein
that, if modiﬁed genetically, is sufﬁcient to cause ALS, arguing
in favor of a potential pathogenic rather than pathological role
of iperOxSOD1. The ﬁnding that only 30% of sALS involves
iperOxSOD1 underscores the concept that, analogous to fALS
(triggered by different genetic mutations), sALS comprises mul-
tiple subgroups with differing etiologies (27). Taken together, our
results indicate the potential to identify biomarkers to subclassify
various forms of ALS.
In iperOxSOD1-sALS, highly oxidized SOD1 is present at
baseline and, in contrast to normally oxidized SOD1 (mutant or
WT), is not sensitive to further oxidation. However, this iper-
OxSOD1 requires further oxidative stress to acquire fully toxic
characteristics leading to aberrant binding with Bcl-2 and mito-
chondrial damage. This ﬁnding is in agreement with previous
studies showing that aberrant misfolding and aggregation of
SOD1 is enhanced by oxidative stress (16). In patient-derived
cells, the extent to which iper-oxidation promotes conforma-
tional modiﬁcations in SOD1 compared with those triggered by
genetic mutations is unclear. From our experiments, it appears
that the structural modiﬁcations induced by genetic mutations
and oxidation differ in nature, with oxidation causing more
subtle changes in SOD1 structure that seem to predispose to
a full modiﬁcation induced by environmental stressors. Indeed,
whereas mutSOD1-containing lymphoblasts form the aberrant
and toxic mutSOD1/Bcl-2 complex at baseline, in the iper-
OxSOD1 lymphoblasts, the appearance of the iperOxSOD1/Bcl-
2 complex and the toxic conformational change in Bcl-2 requires
an additional oxidative stress. Based on our previous studies, we
know that, at least for mutSOD1, the aberrant binding with Bcl-2
is conformation-speciﬁc and requires structural rearrangement
of both proteins (20). By analogy, we believe that the binding
between iperOxSOD1 and Bcl-2 also requires a full structural
rearrangement of SOD1 that for iperOxSOD1-sALS lympho-
blasts is a “two-step” process caused by intrinsic disease-driven
oxidation and extrinsic additional stress.
Both mutSOD1/Bcl-2 and iperOxSOD1/Bcl-2 complexes, but
not H2O2 treatment alone, signiﬁcantly altered mitochondrial
Fig. 5. H2O2-induced formation of the toxic iperOxSOD1/Bcl-2 complex
triggers mitochondrial damage in patient cells. Control and iperOxSOD1-
sALS cells treated for 2 h with 100 μM H2O2 underwent morphological
evaluation by transmission electron microscopy. IperOxSOD1-sALS cells show
derangement of mitochondria matrix and disappearance of morphological
structure.
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morphology in the patients’ lymphoblasts. There was no apparent
cell death, however. Similarly, despite the presence of mutSOD1
or iperOxSOD1, fALS-SOD1 and iperOxSOD1-sALS lympho-
blasts could be easily cultured as control lymphoblasts, probably
because we used immortalized lymphoblasts, which might have
selected for cells inherently more resistant to disease-induced
changes. A careful comparison of lymphocytes and lymphoblasts
of these patients may provide insight into the mechanisms and/or
factors that confer resistance to immortalized cells. Resistance to
SOD1 (mutant or iper-oxidized) toxicity and/or changes induced
by damaged mitochondria also may reﬂect the fact that we used
peripheral and renewable cells that are not affected by ALS. A
comparative analysis of these peripheral cells with induced plu-
ripotent stem cell-derived motor neurons from the same patient
(s) may reveal why motor neurons are more susceptible to mi-
tochondrial changes induced by SOD1 toxicity. Despite the lack
of an evident phenotype (e.g., cell loss), the use of patient lym-
phoblasts has allowed us to identify disease-driven pathogenic
characteristics of an aberrant SOD1 in sALS. We emphasize that
we are not claiming that these—or any other peripheral cells—
represent a viable model for mimicking human disease in culture-
like induced pluripotent stem cell-derived disease-relevant cells
(neurons and glia). Rather, these cells provide a useful “ﬁrst-
pass” screening tool to identify speciﬁc pathogenic signatures of
subgroups of ALS. Of the 20 sALS patients analyzed in the
present study, all 7 with iperOxSOD1 were diagnosed with bulbar
ALS. We found no correlation between iperOxSOD1 and sex,
age of onset, or disease duration. Although the potential corre-
lation between iperOxSOD1 and site of onset requires further
validation using larger cohorts of patients and eventually post-
mortem tissues from subgroups of patients, our data support the
idea of subclassifying ALS based on disease-speciﬁc biochemical
markers. They also support the use of lymphoblasts (or other
readily obtainable peripheral cells) to subclassify complex dis-
eases like ALS by identifying speciﬁc aberrant pathways or tar-
gets, enabling the design of better-tailored therapeutic strategies
with potentially higher efﬁcacy. Interestingly, a recent study found
that reducing SOD1 levels in astrocytes derived from patients
with sALS (with no apparent aberrant SOD1) eliminates the
toxicity of these sporadic astrocytes on motor neurons (23). Al-
though this study conﬁrms the potential to target SOD1 thera-
peutically beyond fALS, it does not identify which population of
sporadic astrocytes has the toxic SOD1 (and thus may beneﬁt
from an SOD1-based therapy), or which form of SOD1 confers
toxicity to these sporadic astrocytes. In the present study, by
showing that aberrant WT SOD1 is iper-oxidized and that iper-
OxSOD1 in sALS seems to correlate with bulbar onset, we pro-
vide these two key elements of the puzzle that may aid the design
of speciﬁc SOD1-based therapies in sALS. Whether the iper-
OxSOD1/Bcl-2 complex is also toxic to astrocyte mitochondria,
and whether it triggers astrocyte-derived toxicity on motor neu-
rons, remain to be determined. However, the notion that Bcl-2 is
a common toxic target of both mutSOD1 and iperOxSOD1 allows
the design of target-based therapies against the SOD1/Bcl-2
complex, whose efﬁcacy may extend beyond application to the
small number of mutSOD1 patients.
Methods
Data were collected from 20 sALS patients with a diagnosis of ALS based on
the revised El Escorial criteria and 4 fALS patients carrying three different
SOD1 mutations (A4V, L106V, and G37R) (Table 1). Ten healthy age-matched
controls were included in the analysis. Ethics Committee approval was
obtained from the Foundation “C. Mondino” Institute of Neurology, Uni-
versity of Pavia (for the sALS patients and controls) and Massachusetts
General Hospital (for the fALS patients). All patients and controls provided
written informed consent to participate in the study. EBV-immortalized
lymphoblasts were derived and analyzed as described in SI Methods.
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